News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TAP Biosystems Release: Top Pharma, Biotechs And CRO Choose Ambr250 Automated Mini Bioreactor System - To Accelerate Their Process Scale-Up Of Biological Therapies And Vaccines



4/29/2014 11:45:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

April 2014 -- TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, today announced that its new ambr250™ automated mini bioreactor system has already been chosen by a number of major pharmaceutical, biotech and CRO firms as a high-throughput, scale-down bioreactor model for their process development and optimisation programmes.

The automated ambr250 system, which has independent parallel control of 12 or 24, single-use 250 mL bioreactors, is being sited at the R&D centres of the top Pharma companies across the US and Europe. The system has also been chosen for the Chinese R & D centre of a major European biopharm; a major CRO in the UK and a UK-based biotech company. The majority of these systems will be used to accelerate mammalian and microbial process development and optimisation of antibody and other protein-based therapeutics. However, three of the systems will be utilised in rapidly developing process optimisation for the production of vaccines.

The companies have chosen the ambr 250 because the high-throughput system has the flexibility to culture mammalian lines including CHO or microbial cells such as Pichia pastoris and E.coli in single-use, stirred bioreactors and utilises continuous pumped feeds, making it possible to fully evaluate the process characteristics of large scale bioreactors and fermenters.

Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems said: “The bioprocessing industry is looking for a realistic scale-down model to accelerate process development and optimize scale-up of cell culture manufacturing processes. The ambr250 system has been rigorously tested by the top pharma firms and it is our expectation that it will be widely adopted across the industry.”

Ngibuini added: “These pharma as well as, CRO and biotech firm installations demonstrate that ambr250 is well-validated, and has universal appeal as an efficient, high-throughput method of scalable process development for a range of industrial cell culture and fermentation applications.”

For further information, please contact:
Matthew Walker, Head of Communications

York Way, Royston, Hertfordshire, SG8 5WY, UK
Tel: +44 1763 227200 Fax: +44 1763 227201

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES